Regeneron CEO discusses Praluent pricing and prescribing trends
Regeneron CEO discusses Praluent pricing and prescribing trends The passage only covers pharmaceutical pricing, market expectations, and physician survey data without linking any high‑profile political figures, intelligence agencies, or major power centers to misconduct. It offers no actionable leads for investigations into wrongdoing. Key insights: Leonard Schleifer, Regeneron CEO, defends Praluent pricing and access.; Praluent priced 46% above Evercore ISI forecast; sales could reach $4.8 B in 2020.; Physicians may prescribe Praluent to 30‑40% of post‑heart‑attack patients.
Summary
Regeneron CEO discusses Praluent pricing and prescribing trends The passage only covers pharmaceutical pricing, market expectations, and physician survey data without linking any high‑profile political figures, intelligence agencies, or major power centers to misconduct. It offers no actionable leads for investigations into wrongdoing. Key insights: Leonard Schleifer, Regeneron CEO, defends Praluent pricing and access.; Praluent priced 46% above Evercore ISI forecast; sales could reach $4.8 B in 2020.; Physicians may prescribe Praluent to 30‑40% of post‑heart‑attack patients.
Tags
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.